Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Molecular and Cellular Biology of Immune Escape in Cancer (J6)


Organizer(s) George C. Prendergast and Dmitry I. Gabrilovich
February 7—12, 2010
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 7, 2009
Late Abstract Deadline: Nov 6, 2009
Scholarship Deadline: Oct 7, 2009
Early Registration Deadline: Dec 7, 2009

Sponsored by Astellas Pharma Inc. and Genentech BioOncology


Summary of Meeting:
It is now widely recognized that the immune microenvironment of a tumor provides critical support in determining its progression versus dormancy or destruction. To gain immune benefits the tumor must evolve mechanisms of immune escape. Study of this crucial process requires cross-fertilization between molecular cell biologists and tumor immunologists who do not tend to interact. This problem is also integrated with the problem of cancer inflammation that has captured the attention of tumor biologists focused on transgenic mouse models and clinical settings. Thus, we propose a unique conference – the first of its kind – to integrate perspectives from a diverse set of researchers in cancer, immunology, and molecular therapeutics and to focus specifically on immune escape and tumor-induced immune suppression as a multidisciplinary problem. Cancer is initiated by the accumulation of genetic and epigenetic changes in a normal cell, but its progression depends on the stromal and immune microenvironment of the initiated cell. While intrinsic signals within the initiated cell drive neoplastic transformation and genomic plasticity, extrinsic signals delivered by immune cells are critical in dictating whether progression versus dormancy or destruction of an initiated lesion takes place, and also whether metastasis may occur. The high degree of genomic plasticity in cancer cells permits them to develop sophisticated ways to prevent the immune system from recognizing and eliminating tumor cells. It has become increasingly clear in recent years that abnormalities in the immune system that are induced by tumors not only hamper natural anti-tumor immune surveillance but also limit the efficacy of immunotherapy and even traditional chemotherapy and radiotherapy. Thus, tumor-induced immune abnormalities may not only impact the clinical course of disease but also the prospects for its therapeutic management. Recent results indicate that we are on the verge of a real breakthrough in our understanding of how tumors thwart the immune system and how correcting immune escape could vastly improve cancer therapy. However, at present the available mechanistic information presents a somewhat convoluted picture that includes some seemingly contradictory elements. While this situation is a natural stage of development in the field, there is nevertheless a pressing need to define key questions and organize their development in coherent ways that can speed improvements in cancer therapy.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 7

15:00—19:30
Registration

Longs Peak Foyer
18:30—19:30
Refreshments

Longs Peak Foyer
19:30—21:30
Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Nina Bhardwaj, Ichan School of Medicine at Mt Sinai, USA

* Dmitry I. Gabrilovich, Wistar Institute, USA

* George C. Prendergast, Lankenau Institute for Medical Research, USA

* Giorgio Trinchieri, NCI, National Institutes of Health, USA

Robert D. Schreiber, Washington University School of Medicine, USA
Co-Evolution of Immunoediting on Oncogenesis during Tumor Formation

Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, UK
Inflammatory Cytokines and Autocrine Tumor-Promoting Networks


MONDAY, FEBRUARY 8

07:00—08:00
Breakfast

Quandary
08:00—11:15
Tumor Microenvironment and Immune Escape (Joint)
Meeting has ended...abstracts no longer viewable online.
This session will be focused on how stromal cells, inflammation, and angiogenesis support malignant progression, highlighting crucial roles for immune cells in contributing to these processes.

Grays/Longs Peak
* Robert D. Schreiber, Washington University School of Medicine, USA

Lisa M. Coussens, Oregon Health & Science University, USA
Role of Inflammation in Tumor Progression

Claire E. Lewis, University of Sheffield Medical School, UK
Role of Macrophages in Tumor Progression and Response to Therapy

Arya Biragyn, NIA, National Institutes of Health, USA
Short Talk: Primary Breast Cancer Actively Generates Regulatory T and B Cells (Tregs and Bregs) to Facilitate Lung Metastasis

Gerard I. Evan, University of Cambridge, UK
Immune Function and Angiogenesis in Myc-mediated Tumor Formation

Hans Schreiber, University of Chicago, USA
The Role of Tumor Stroma in Immune Escape of Cancer

Esteban Celis, Moffitt Cancer Center, USA
Short Talk: Interferon-gamma Induced T Cell Epitope Purging: Another Mode of Tumor Immune Escape?

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Quandary
13:00—22:00
Poster Viewing

Quandary
14:30—16:30
Workshop 1: Regulation of Immune Escape by Microenvironment
This session will deepen understanding of the critical role of the tumor microenvironment in driving malignant progression.

Longs Peak
* Dmitry I. Gabrilovich, Wistar Institute, USA

Srinivas Nagaraj, University of South Florida, College of Medicine, USA
Regulation of Myeloid-Derived Suppressor Cell Activity in Cancer by CD4+ T Cells

Cassie K. Chou, University of Washington, USA
Abrogation of TGFbeta Signaling Leads to Increased Persistence of Prostate Self/Tumor Antigen Specific CD8 T Cells but does not Completely Prevent Tolerization

Luca Vago, IRCCS H San Raffaele, Italy
Loss of Mismatched HLA as a Mechanism of Leukemia Immune Escape in Family Haploidentical and Unrelated HSCT

Philippe Foubert, Genomics Institute of the Novartis Research Foundation, USA
Blockade of Myeloid Cell Trafficking by Inhibiting a PI3-Kinase gamma-alpha4 Integrin Activation Pathway Stimulates Anti-Tumor Immunity

Sheng Wei, Moffitt Cancer Center, USA
Myeloid-Derived Suppressor Cells (MDSC) are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS)

Michael S. Leibowitz, University of Pittsburgh, USA
TAP1/2 Downregulation and CTL Evasion is Independent of STAT3 Activation in Head and Neck Cancer Cells

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Antigen-Specific Mechanisms of Tumor Escape
Meeting has ended...abstracts no longer viewable online.
This session will be focused on molecular and cellular mechanisms associated with role of antigens in tumor escape. Topics include tumor antigen diversity, molecular mechanisms of defective antigen presentation by tumor cells, dendritic cells and T cell tolerance.

Longs Peak
* Hans Schreiber, University of Chicago, USA

Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany
No Escape

Michael R. Shurin, University of Pittsburgh, USA
Dendritic Cells in Immune Escape in Cancer

Richard A. Flavell, HHMI/Yale University School of Medicine, USA
TGF-beta Signaling in Tumoral Immune Suppression

Andrew D.M. Kaiser, Netherlands Cancer Institute, Netherlands
Short Talk: Low Tumor-Antigen Density Leads to PD-L1/PD-1 Mediated Suppression of Partially Exhausted CD8+ T Cells


Following Session is for Role of Inflammation in Oncogenesis (J5)

17:00—19:00
Inflammation in the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, UK

Alberto Mantovani, Humanitas University, Italy
Tumor Microenvironment: Sculpting the Inflammatory Response during Tumor Formation

Susan E. Erdman, Massachusetts Institute of Technology, USA
Unifying Roles for Regulatory T Cells and Inflammation in Cancer

Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia
IL-23 Suppresses Innate Immune Response during Carcinogenesis and Metastasis

19:00—20:00
Social Hour with Lite Bites

Quandary
19:30—22:00
Poster Session 1

Quandary

TUESDAY, FEBRUARY 9

07:00—08:00
Breakfast

Quandary
08:00—11:15
Myeloid Cells in Immune Suppression and Tumor Progression
Meeting has ended...abstracts no longer viewable online.
This session will focus on the molecular and cellular mechanisms of immunosuppression by different types of myeloid cells.

Longs Peak
* Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori, Italy

Dmitry I. Gabrilovich, Wistar Institute, USA
Regulation of Myeloid-Derived Suppressor Cells in Cancer

David H. Munn, Georgia Regents University, USA
Indoleamine 2,3-Dioxygenase in Tumor Immune Escape

David R. Gibb, Virginia Commonwealth University, USA
and

Sheinei Jamal Saleem, Virginia Commonwealth University, USA
Short Talk: A Novel Model of Myeloid-Derived Suppression of the Anti-Tumor Response: Overexpression of ADAM10 Promotes Myeloid-Derived Suppressor Cell Expansion in a Tumor-Free Environment

Vincenzo Bronte, University of Verona, Italy
Forced Myelopoiesis and Immune Deviation in Cancer

Ling Qi, Cornell University, USA
Short Talk: The Metabolic Function of Myeloid-Derived Suppressor Cells in Obesity

Cong Yan, Indiana University School of Medicine, USA
Short Talk: Apoptotic Inhibition of Myeloid Cells Causes MDSC Expansion and Lung Tumorigenesis

Anna Wasiuk, Oregon Health & Science University, USA
Short Talk: Mast Cells as Regulators of Adaptive Immunity to Tumors


Following Session is for Role of Inflammation in Oncogenesis (J5)

08:00—11:15
Inflammation and Carcinogenesis
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Alberto Mantovani, Humanitas University, Italy

Eva M. Hernando, New York University Cancer Center, USA
miRNAs that Contribute to Melanoma Metastasis by Modulating Immune Evasion

Yinling Hu, National Cancer Institute at Frederick, USA
Role of IKKalpha in Skin Cancer

Pauline M. Andreu, University of California San Francisco, USA
Short Talk: FcRgamma Activation Regulates Inflammation-Associated Squamous Carcinogenesis

Giorgio Trinchieri, NCI, National Institutes of Health, USA
Innate Resistance and Cancerogenesis

Carlos Bais, Genentech, Inc., USA
Stromal Cells and VEGF-Independent Angiogenesis

Brendan J. Jenkins, Hudson Institute of Medical Research, Australia
Short Talk: Deregulated Cytokine Signaling as a Crucial Bridge Linking Pathogen-Driven Gastric Inflammation and Tumorigenesis

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Quandary
13:00—22:00
Poster Viewing

Quandary

Following Session is for Role of Inflammation in Oncogenesis (J5)

14:30—16:30
Workshop: Inflammation and Carcinogenesis
This session will focus on the role of inflammatory cytokines, immunosuppressive factors and innate immune cells in modulating growth of cancer. The session will cover relevant signaling pathways, contribution of tumor invasive macrophages and dendritic cells and effects on the tumor micro-environment.

Grays Peak
* Jacqueline F. Bromberg, Memorial Sloan Kettering Cancer Center, USA

* Carlos Bais, Genentech, Inc., USA

David G. DeNardo, Washington University Medical School, USA
CD4+ T Lymphocytes Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing the Pro-Tumor Properties of Macrophages

Mercedes B. Fuertes, University of Chicago, USA
Host Type I IFN Signals Mediate Awareness of Tumor and Promote Spontaneous Adaptive Immune Responses Against Tumor-Associated Antigens

Esther N. Arwert, Francis Crick Institute, UK
Tumor Formation Initiated by Nondividing Epidermal Cells via an Inflammatory Infiltrate

Jack D. Bui, University of California, San Diego, USA
Evidence for Macrophage-Mediated Cancer Immunoediting

Sharon A. Glynn, National University of Ireland Galway, Ireland
Joint Expression of NOS2 and COX2 in ER-Negative Breast Cancer – Acquisition of a Poor Prognosis Phenotype

Abby L. Geis, Arkansas College of Osteopathic Medicine, USA
A Human Commensal Promotes Colorectal Cancer in Min Mice: Role of the Treg / Th17 Balance in the colitis-Induced Carcinogenesis

Maria Grazia Ruocco, Skirball, New York University School of Medicine, USA
Stress-Induced Signals Facilitate T Cell Arrest and Lead to Tumor Eradication

Li Yang, NCI, National Institutes of Health, USA
Short Talk: TGFbeta, an Inflammation and Immune Suppressor in Tumor Progression

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Regulatory T and NKT Cells in Immune Escape
Meeting has ended...abstracts no longer viewable online.
This session is focused on molecular and cellular mechanisms of regulatory T cell function in cancers. Specific topics can include novel findings on the role of classical Treg in cancer, different types of Tregs, and role of NKT.

Longs Peak
* Vincenzo Bronte, University of Verona, Italy

Harald von Boehmer, Harvard Medical School, USA
In vivo Induction of Antigen-Specific Regulatory T Cells to Prevent Unwanted Immunity

Rong-Fu Wang, Baylor College of Medicine, USA
Immunosuppressive gammadelta Treg and other Immune Cells and their Functional Regulation through Innate Immune Signaling

Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori, Italy
OX40 Costimulation in Treg Functions

Jay A. Berzofsky, NCI, National Institutes of Health, USA
Short Talk: Tipping the Balance in the NKT Cell Regulation of Tumor Immunity


Following Session is for Role of Inflammation in Oncogenesis (J5)

17:00—19:00
Innate Resistance and Tumor Escape
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Nina Bhardwaj, Ichan School of Medicine at Mt Sinai, USA

David H. Raulet, University of California, Berkeley, USA
NKG2D, NKG2D Ligands and Spontaneous Malignancy

Laurence Zitvogel, Institut Gustave Roussy, France
NKp30/NCR3 Isoforms and Prognosis of Human Malignancies: Revisiting the DC/NK Cross Talk

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Suppression and Innate Immune Surveillance

19:00—20:00
Social Hour with Lite Bites

Quandary
19:30—22:00
Poster Session 2

Quandary

WEDNESDAY, FEBRUARY 10

07:00—08:00
Breakfast

Quandary
08:00—11:15
Transcriptional Regulation of Immune Escape (Joint)
Meeting has ended...abstracts no longer viewable online.
Session will discuss regulation of gene expression implicated in tumor progression and immune escape, including possible modifier effects and relationship to metastastic efficiency.

Grays/Longs Peak
* George C. Prendergast, Lankenau Institute for Medical Research, USA

Hua E. Yu, Beckman Research Institute, City of Hope, USA
STAT3 in Cancer Inflammation and Immune Escape

Erwin F. Wagner, Spanish National Cancer Research Centre, Spain
Stress-responsive and context dependent transcription factor complex

Mitsugu Fujita, University of Pittsburgh Cancer Institute, USA
A Pivotal Role of Type-1 Interferons in Anti-glioma Immunosurveillance

Thomas Gajewski, University of Chicago, USA
Transcriptional regulation of T cell anergy: Implications for cancer immunotherapy

Michael Karin, University of California, San Diego, USA
Tumor elicited inflammation and lymphocyte infiltrates in metastatic progression

Jahan Khalili, MD Anderson Cancer Center, USA
Short Talk: The Role of B-raf V600E Mutation on PD-1 Ligand Expression in Melanocytic nevi

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Quandary
13:00—22:00
Poster Viewing

Quandary
14:30—16:30
Workshop 2: Tumor Recruitment of Immune Cells: Roles in Tumor Progression and Immune Escape
Consider roles for MDSCs, B cells, mast cells, microvesicle transfer, etc.

Longs Peak
* Michael R. Shurin, University of Pittsburgh, USA

Courtney Smith, Lankenau Institute for Medical Research, USA
Indoleamine 2,3-Dioxygenase (IDO) Supports Metastatic Outgrowth of the 4T1 Breast Cancer Mouse Model

Melody A. Swartz, University of Chicago, USA
Lymph Node Mimicry by Tumors Promotes Immunological Tolerance

Stephanie Watkins, National Cancer Institute, National Institutes of Health, USA
Prostate Tumor-Associated Dendritic Cell Induction of Tolerance and Suppressor Activity in Tumor-Infiltrating CTLs is Associated with FOXO3a Expression

Rongcun Yang, Nankai University, China
Suppressor of Cytokine Signaling-3 (SOCS3) Downregulates the Ability of Pyruvate Kinase Type M2 to Cause Dendritic Cell Dysfunction

Kyle C. McKenna, University of Pittsburgh, USA
Short Talk: Inhibited Function of Intratumoral F4/80+ Macrophages Contributes to the Failure of CD8+ CTL to Control Ocular Tumor Development

Andreas Herrmann, Beckman Research Institute, USA
Short Talk: Stat3 is a Molecular Target for Improving Adoptive T cell Therapy

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Immune Inhibitory Receptors in Cancer
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Augusto C. Ochoa, Louisiana State University Health Sciences Center, USA

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Mechanism of T-Cell Tolerance in Cancer Mediated by Inhibitory Receptors

Hyam I. Levitsky, Juno Therapeutics, USA
Mechanism of T-Cell Tolerance in Cancer

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Short Talk: Official title unknown. Topic was IL-35 and its role in regulation of T cell function

George Coukos, University Hospital of Lausanne - CHUV, Switzerland
Hypoxia Recruits Regulatory T Cells via the CCL28 Chemokine to Promote Tolerance and Angiogenesis in Cancer

Daniel Hirschhorn-Cymerman, Memorial Sloan-Kettering Cancer Center, USA
Short Talk: OX40 Engagement and Chemotherapy Combination Provides Potent Anti-Tumor Immunity with Concomitant Regulatory T Cell Apoptosis


Following Session is for Role of Inflammation in Oncogenesis (J5)

17:00—19:00
Innate Receptors, Cancer and Inflammation
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia

Xiaoxia Li, Cleveland Clinic Foundation, USA
SIGIRR-Mediated Tumor Suppression

Felix Yarovinsky, University of Rochester Medical Center, USA
Short Talk: A Novel Transgenic Mouse Model for Chronic Inflammation: Linking Toll-like Receptor (TLR) Responses with Carcinogenesis

Nina Linde, German Cancer Research Center (DKFZ), Germany
Inflammation in Epithelial Skin Tumors

Irving C. Allen, Virginia Tech, USA
Short Talk: NLRP3 is an Essential Regulator of Interleukin-1beta and Interleukin-18 during Inflammation Driven Colon Tumorigenesis

19:00—20:00
Social Hour with Lite Bites

Quandary
19:30—22:00
Poster Session 3

Quandary

THURSDAY, FEBRUARY 11

07:00—08:00
Breakfast

Quandary
08:00—11:15
Metabolic Pathways Involved in Immune Escape
Meeting has ended...abstracts no longer viewable online.
This session will be focused on the role of metabolism of carbohydrates, lipids, arginine, tryptophan, and exosomes in tumor escape.

Longs Peak
* Drew M. Pardoll, Johns Hopkins University School of Medicine, USA

Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental, Argentina
'Turning Sweet' on Immunity: Galectin-Glycan Interactions in T-Cell and Dendritic Cell Physiology

Suzanne Ostrand-Rosenberg, University of Maryland, USA
Myeloid Cells, Inflammation, and Anti-Tumor Immunity: Not an Auspicious Combination

Linglin Yang, University of Maryland, Baltimore County, USA
Short Talk: Indoleamine 2,3-Dioxygenase (IDO) Contributes to Myeloid-Derived Suppressor Cell- Mediated Tumor Suppression through Interleukin-6 Signaling Pathway

Augusto C. Ochoa, Louisiana State University Health Sciences Center, USA
Arginine Depletion by MDSC in vivo, a Mechanism of Tumor Escape

Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori, Italy
Tumor-Derived Microvesicles and Immune Defects in Human Cancer

Jonathan D. Silk, University of Oxford, UK
Short Talk: A Novel Amino Acid Transporter Induced by Expression of Indoleamine 2,3 Dioxygenase in Tumors


Following Session is for Role of Inflammation in Oncogenesis (J5)

08:00—11:00
Dendritic Cells and Macrophages in Cancer
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Laurence Zitvogel, Institut Gustave Roussy, France

Nina Bhardwaj, Ichan School of Medicine at Mt Sinai, USA
Modulating Inflammatory Dendritic Cell Responses against Cancer

Shannon J. Turley, Genentech, Inc., USA
Novel Aspects of Tolerance in the Tumor Microenvironment

Miriam Merad, Mount Sinai School of Medicine, USA
Identification of a DC lineage with unique functions in tissues immunity

Ana Carrizosa Anderson, Harvard Medical School, USA
New Roles for TIM Family Members in Immune Regulation

Emmanuelle Godefroy, New York University, School of Medicine, USA
Short Talk: MMP-2 Conditions Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12 and OX40L-Dependent Pathway

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15
On Own for Lunch and Recreation

14:30—16:30
Workshop 3: Novel Strategies to Reverse Immune Escape in Cancer
Will discuss novel approaches to reversal of immune defects in cancer. Topics may include cytokines supporting productive immune response, block of inhibitory cytokines and receptors, regulation of immune responses via toll-like receptors, etc.

Longs Peak
Juan R. Cubillos-Ruiz, Weill Cornell Medical College, USA
siRNA Delivery through Novel TLR5-Agonist Polyethylenimine Reprograms Tumor-Associated Regulatory Dendritic Cells to Elicit Therapeutic Immunity

Viktor Umansky, German Cancer Research Center, Germany
Blocking of Myeloid Derived Suppressor Cell (MDSC) Functions Results in Antitumor Effects in Ret Transgenic Mouse Melanoma Model

Xiangdong Liu, Incyte Corporation, USA
INCB24360, a Potent and Selective Inhibitor of Indoleamine 2,3-dioxygenase (IDO) for Cancer Immunotherapy

Ge Ma, Mount Sinai School of Medicine, USA
Paired Immunoglobin Like Receptor-B (PIRB) Regulates the Suppressive Function and M1 versus M2 Differentiation of MDSC

Carl E. Ruby, Rush University Medical Center, USA
Characterizing the Effect of Aging in Tumor-Bearing Hosts Treated with OX40 Agonists

Thorbald van Hall, Leiden University Medical Center, Netherlands
A Novel Category of Tumor Antigens Enable CTL Immunity to Tumor Escape Variants

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:15
Therapeutic Development to Correct Immune Escape in Cancer
Meeting has ended...abstracts no longer viewable online.
This session will discuss preclinical and clinical development of different approaches to counter immune suppressive mechanisms in cancer.

Longs Peak
* Hyam I. Levitsky, Juno Therapeutics, USA

George C. Prendergast, Lankenau Institute for Medical Research, USA
Regulation and Therapeutic Inhibition of IDO/IDO2 in Cancer

Alexander J. Muller, Lankenau Institute for Medical Research, USA
Short Talk: IDO Contributes to Pathologies Associated with Chronic Inflammation

Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
The Whys and Wherefores of CTLA-4 Blockade

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Modulating Anti-tumor Immunity through Checkpoint Blockade: B7-H1/PD-1 Interactions

Jeffrey Weber, NYU Langone Medical Center, USA
Regulation of Immune Responses in Cancer via Checkpoint Blockade of Negative Receptors in Melanoma


Following Session is for Role of Inflammation in Oncogenesis (J5)

17:00—19:00
Cytokines in the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Giorgio Trinchieri, NCI, National Institutes of Health, USA

Jacqueline F. Bromberg, Memorial Sloan Kettering Cancer Center, USA
The IL-6/Stat3 Signaling Pathway Promotes Mammary Tumorigenesis and Metastases

Martin Oft, ARMO BioSciences, USA
Switching Tumor Promoting Inflammation into Tumor Immune Surveillance

Charles Drake, Johns Hopkins University, USA
Th17 Cells in Tumors

Jiyoung Park, Ulsan National Institute of Science and Technology, South Korea
Short Talk: Peripheral Leptin Promotes Mammary Tumor Progression and Metastasis through Activation of the Jak2/STAT3 Pathway in vivo

Alexander J. Muller, Lankenau Institute for Medical Research, USA
Short Talk: IDO Contributes to Pathologies Associated with Chronic Inflammation

19:15—20:15
Social Hour with Lite Bites

Quandary
20:15—23:00
Entertainment

Quandary

FRIDAY, FEBRUARY 12

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA144231-01




We gratefully acknowledge additional support for this conference from:

Astellas Pharma Inc. CytoAnalytics
Genentech BioOncology Royal Society of Chemistry

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676